Fed Governor Adriana Kugler to resign
BOSTON—Daniel K. Mahoney, Executive Vice President, Chief Financial Officer, and Treasurer of CRA International , Inc. (NASDAQ:CRAI), a $1.19 billion market cap consulting firm, recently sold shares of the company, according to a regulatory filing. The stock has experienced an 8.25% decline over the past week, currently trading at $174.28.
On March 6, Mahoney sold a total of 1,000 shares of common stock in three separate transactions. The shares were sold at prices ranging from $184.05 to $188.16, resulting in a total transaction value of $185,802. Following these transactions, Mahoney holds 12,153 shares directly. According to InvestingPro, the company maintains good financial health with a 10.17% revenue growth over the last twelve months.
These sales were conducted under a prearranged Rule 10b5-1 trading plan, which Mahoney adopted on August 8, 2024. This plan allows insiders to set up a predetermined schedule for selling stocks, helping to avoid any potential accusations of insider trading.
CRA International, a Boston-based company, provides economic, financial, and management consulting services.
In other recent news, Charles River Associates (CRA) reported impressive fourth-quarter earnings for 2024, outperforming analyst projections. The company achieved earnings per share (EPS) of $2.03, surpassing the anticipated $1.62, and recorded revenue of $176.4 million, exceeding the forecasted $166.87 million. This revenue marks the highest in the company’s history, reflecting a 9.2% increase compared to the previous year. CRA’s legal and regulatory services experienced a 12% growth year-over-year, contributing significantly to the overall revenue increase. Looking ahead, CRA has provided optimistic revenue guidance for fiscal year 2025, estimating between $715 million and $735 million. The firm also aims for a non-GAAP EBITDA margin target of 12-13%. Analysts from firms like Sidoti and Barrington Research have noted the company’s strong performance and solid outlook. CRA’s strategic focus on expanding its life sciences and management consulting practices is expected to support future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.